Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10875-021-01046-y http://scihub22266oqcxt.onion/10.1007/s10875-021-01046-y 33983545!8117127!33983545     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Immunol 2021 ; 41 (6): 1146-1153 Nephropedia Template TP {{tp|p=33983545|t=2021. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency |pdf=|usr=}}{{33983545}} gab.com Text Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency JO: J Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33983545 #FOAvip Immunocompromised patients, including those with inborn errors of immunity (IEI), may be at increased risk for severe or prolonged infections with SARS-CoV-2 (Zhu et al. N Engl J Med. 382:727-33, 2020; Guan et al. 2020; Minotti et al. J Infect. 81:e61-6, 2020). While antibody and T cell responses to SARS-CoV-2 structural proteins are well described in healthy convalescent donors, adaptive humoral and cellular immunity has not yet been characterized in patients with antibody deficiency (Grifoni et al. Cell. 181:1489-1501 e1415, 2020; Burbelo et al. 2020; Long et al. Nat Med. 26:845-8, 2020; Braun et al. 2020). Herein, we describe the clinical course, antibody, and T cell responses to SARS-CoV-2 structural proteins in a cohort of adult and pediatric patients with antibody deficiencies (n = 5) and controls (related and unrelated) infected with SARS-CoV-2. Five patients within the same family (3 with antibody deficiency, 2 immunocompetent controls) showed antibody responses to nucleocapsid and spike proteins, as well as SARS-CoV-2 specific T cell immunity at days 65-84 from onset of symptoms. No significant difference was identified between immunocompromised patients and controls. Two additional unrelated, adult patients with common variable immune deficiency were assessed. One did not show antibody response, but both demonstrated SARS-CoV-2-specific T cell immunity when evaluated 33 and 76 days, respectively, following SARS-CoV-2 diagnosis. This report is the first to show robust T cell activity and humoral immunity against SARS-CoV-2 structural proteins in some patients with antibody deficiency. Given the reliance on spike protein in most candidate vaccines (Folegatti et al. Lancet. 396:467-78, 2020; Jackson et al. N Engl J Med. 383:1920-31, 2020), the responses are encouraging. Additional studies will be needed to further define the timing of onset of immunity, longevity of the immune response, and variability of response in immunocompromised patients. Twit Text FOAVip Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency ????J Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33983545 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33983545 #FOAvip English Wikipedia <ref>{{Cite pmid|33983545}}</ref> Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency #MMPMID33983545 Kinoshita H; Durkee-Shock J; Jensen-Wachspress M; Kankate VV; Lang H; Lazarski CA; Keswani A; Webber KC; Montgomery-Recht K; Walkiewicz M; Notarangelo LD; Burbelo PD; Fuss I; Cohen JI; Bollard CM; Keller MD J Clin Immunol 2021[Aug]; 41 (6): 1146-1153 PMID33983545show ga Immunocompromised patients, including those with inborn errors of immunity (IEI), may be at increased risk for severe or prolonged infections with SARS-CoV-2 (Zhu et al. N Engl J Med. 382:727-33, 2020; Guan et al. 2020; Minotti et al. J Infect. 81:e61-6, 2020). While antibody and T cell responses to SARS-CoV-2 structural proteins are well described in healthy convalescent donors, adaptive humoral and cellular immunity has not yet been characterized in patients with antibody deficiency (Grifoni et al. Cell. 181:1489-1501 e1415, 2020; Burbelo et al. 2020; Long et al. Nat Med. 26:845-8, 2020; Braun et al. 2020). Herein, we describe the clinical course, antibody, and T cell responses to SARS-CoV-2 structural proteins in a cohort of adult and pediatric patients with antibody deficiencies (n = 5) and controls (related and unrelated) infected with SARS-CoV-2. Five patients within the same family (3 with antibody deficiency, 2 immunocompetent controls) showed antibody responses to nucleocapsid and spike proteins, as well as SARS-CoV-2 specific T cell immunity at days 65-84 from onset of symptoms. No significant difference was identified between immunocompromised patients and controls. Two additional unrelated, adult patients with common variable immune deficiency were assessed. One did not show antibody response, but both demonstrated SARS-CoV-2-specific T cell immunity when evaluated 33 and 76 days, respectively, following SARS-CoV-2 diagnosis. This report is the first to show robust T cell activity and humoral immunity against SARS-CoV-2 structural proteins in some patients with antibody deficiency. Given the reliance on spike protein in most candidate vaccines (Folegatti et al. Lancet. 396:467-78, 2020; Jackson et al. N Engl J Med. 383:1920-31, 2020), the responses are encouraging. Additional studies will be needed to further define the timing of onset of immunity, longevity of the immune response, and variability of response in immunocompromised patients. |Adolescent[MESH] |Adult[MESH] |Antibodies, Viral/*blood[MESH] |COVID-19/*immunology[MESH] |Carrier State[MESH] |Cells, Cultured[MESH] |Child[MESH] |Common Variable Immunodeficiency/*immunology[MESH] |Exome Sequencing[MESH] |Female[MESH] |Humans[MESH] |Immunity, Humoral[MESH] |Lymphocyte Activation[MESH] |Male[MESH] |Middle Aged[MESH] |Mutation/genetics[MESH] |Pedigree[MESH] |SARS-CoV-2/*physiology[MESH] |T-Lymphocytes/*immunology[MESH] |Transmembrane Activator and CAML Interactor Protein/genetics[MESH]Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with An(epmc).pdf DeepDyve Pubget Overpricing